Evidence map›Paper›PMID 38200158›Full record

ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Advances in the treatment of malignant ascites in China.

Junzi Zhang, Zhaoxue Qi, Wenjie Ou, Xuguang Mi, Yanqiu Fang, Wenqi Zhang, Zhen Yang, Ying Zhou, Xiuying Lin, Junjie Hou and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Junzi ZhangChangchun University of Chinese Medicine, Changchun, Jilin, China.
Zhaoxue QiDepartment of Secretory Metabolism, The First Hospital of Jilin University, Changchun, China.
Wenjie OuChangchun University of Chinese Medicine, Changchun, Jilin, China.
Xuguang MiDepartment of Central Laboratory, Jilin Provincial People's Hospital, Changchun, China.
Yanqiu FangDepartment of Tumor Comprehensive Therapy, Jilin Provincial People's Hospital, Changchun, China.
Wenqi ZhangChangchun University of Chinese Medicine, Changchun, Jilin, China.
Zhen YangChangchun University of Chinese Medicine, Changchun, Jilin, China.
Ying ZhouDepartment of Tumor Comprehensive Therapy, Jilin Provincial People's Hospital, Changchun, China.
Xiuying LinDepartment of Tumor Comprehensive Therapy, Jilin Provincial People's Hospital, Changchun, China.
Junjie HouDepartment of Tumor Comprehensive Therapy, Jilin Provincial People's Hospital, Changchun, China. houjunjie1979@163.com.
Zhixin YuanDepartment of Emergency Surgery, Jilin Provincial People's Hospital, Changchun, China. doctorzx2023@163.com.
Changchun University of Chinese Medicine · CNPeople 's Hospital of Jilin Province · CNFirst Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMalignant ascites (MA) often occurs in recurrent abdominal malignant tumors, and the large amount of ascites associated with cancerous peritonitis not only leads to severe abdominal distension and breathing difficulties, but also reduces the patient's quality of life and ability to resist diseases, which usually makes it difficult to carry out anti-cancer treatment. The exploration of MA treatment methods is also a key link in MA treatment. This article is going to review the treatment of MA, to provide details for further research on the treatment of MA, and to provide some guidance for the clinical treatment of MA.

methodThis review analyzes various expert papers and summarizes them to obtain the paper.

resultThere are various treatment methods for MA, including systemic therapy and local therapy. Among them, systemic therapy includes diuretic therapy, chemotherapy, immunotherapy, targeted therapy, anti angiogenic therapy, CAR-T, and vaccine. Local therapy includes puncture surgery, peritoneal vein shunt surgery, acellular ascites infusion therapy, radioactive nuclide intraperitoneal injection therapy, tunnel catheter, and intraperitoneal hyperthermia chemotherapy. And traditional Chinese medicine treatment has also played a role in enhancing efficacy and reducing toxicity to a certain extent.

conclusionAlthough there has been significant progress in the treatment of MA, it is still one of the clinical difficulties. Exploring the combination or method of drugs with the best therapeutic effect and the least adverse reactions to control MA is still an urgent problem to be solved.

Indexed as

CarcinomaPeritoneal NeoplasmsAscitesChinaHumansImmunotherapyNeoplasm Recurrence, LocalQuality of LifeCancerCAR-T therapyImmunityMalignant ascitesPeritoneal disseminationTraditional Chinese medicine

Identifiers

PMID38200158
OpenAlexW4390793664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.